Key result
NLRP3 inhibition with MCC950 reduces myocardial inflammation in experimental autoimmune myocarditis by restoring Th17/Treg balance.
Why the study?
The study aimed to investigate whether the NLRP3 inflammasome modulates the Th17/Treg cell balance in experimental autoimmune myocarditis.
Does NLRP3 inhibition with MCC950 attenuate myocardial inflammation and restore Th17/Treg balance in a mouse model of experimental autoimmune myocarditis?
Does NLRP3 inhibition with MCC950 attenuate myocardial inflammation and restore Th17/Treg balance in a mouse model of experimental autoimmune myocarditis?
NLRP3 inflammasome inhibition with MCC950 attenuates myocardial injury in experimental autoimmune myocarditis by directly intrinsically regulating naive CD4+ T cells to restore the Th17/Treg balance.
Answers are grounded in this paper and cite their sources.
May inform NLRP3-targeted therapies for myocarditis; hypothesis-generating in mice, requiring human trials before any clinical consideration.
This study aimed to investigate whether the NLRP3 inflammasome modulates the Th17/Treg cell balance in experimental autoimmune myocarditis (EAM). BALB/c mice were immunized subcutaneously with purified cardiac myosin heavy chain-α to induce EAM, injected NLRP3 inhibitor (MCC950) or PBS into the EAM mice by intraperitoneal injection. Splenic CD4 + T cells were isolated for in vitro culture. Myocardial inflammation was evaluated by HE staining. Th17/Treg ratios were analyzed by flow cytometry in cardiac tissue and cultured cells. RORγt and Foxp3 mRNA expression was measured by RT-PCR and IL-17/IL-10 levels by ELISA. Our study demonstrates that NLRP3 inhibition significantly attenuates myocardial inflammatory cell infiltration and preserves cardiac architecture in EAM mice. The EAM group exhibited significantly increased Th17/Treg ratios and RORγt mRNA expression in myocardial tissue compared to both MCC950-treated and control groups while demonstrating markedly decreased Foxp3 mRNA levels. In vitro experiments using cultured CD4 + T cells revealed substantially higher Th17 cell proportions, RORγt expression, and IL-17 secretion in the EAM group versus MCC950-treated cells, accompanied by significantly reduced Treg cell frequencies, Foxp3 mRNA levels, and IL-10 production. During the pathogenesis of experimental autoimmune myocarditis (EAM), the NLRP3 inflammasome promotes Th17 cell differentiation while suppressing Treg cell development. Inhibition of the NLRP3 inflammasome restores the Th17/Treg balance and mitigates myocardial injury. These findings suggest that the NLRP3 inflammasome is a critical signaling hub in modulating immune responses in EAM. Targeting NLRP3 may represent a novel immunotherapeutic strategy for myocarditis. • NLRP3 inhibition reduces myocardial inflammation and preserves cardiac structure in EAM mice model. • NLRP3 blockade restores Th17/Treg balance, enhancing Treg cells in EAM mice. • NLRP3 inhibition modulates ROR-γt/Foxp3, shifting T cell differentiation to Tregs. • Targeting NLRP3 inflammasome offers novel immunotherapeutic strategy for myocarditis.
No takes yet. Share an insight, caveat, or question.
Su et al. (2026) studied Experimental Autoimmune Myocarditis. MCC950 vs. PBS was evaluated on Myocardial inflammation severity and Th17/Treg cell ratios (p=<0.05). Inhibition of the NLRP3 inflammasome with MCC950 significantly attenuated myocardial inflammation and preserved cardiac architecture by restoring the Th17/Treg balance in mice with experimental autoimmune myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: